Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723602 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
A Phase 1 study, sponsored by Albert B. Sabin Vaccine Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04723602 is a Phase 1 study that has completed, run by Albert B. Sabin Vaccine Institute. The registered enrollment target is 32 participants.
The verdict
NCT04723602, a Phase 1 study, has completed, sponsored by Albert B. Sabin Vaccine Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Primary Objective: • To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10\^11 particle units (PU) to healthy adults. Secondary Objectives: * To evaluate the antibody response to Monovalent Chimpanzee Adenoviral Vectored Filovirus Ebola-S (cAd3-EBO-S) and Monovalent Chimpanzee Adenoviral Vectored Filovirus (Marburg) (cAd3 Marburg) vaccines as assessed by antigen glycoprotein (GP) specific (enzyme-linked immunosorbent assay) ELISA * To collect sufficient post-vaccination plasma to support further development of filovirus assays
Interventions
- BIOLOGICAL cAd3-Marburg
- BIOLOGICAL cAd3-EBO-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-01-06 |
| Est. Completion | 2021-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04723602
The ClinicalTrials.gov registry entry for NCT04723602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert B. Sabin Vaccine Institute, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cAd3-Marburg is the first listed.
NCT04723602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04723602 about?
NCT04723602 is a clinical study titled "Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults". Primary Objective: • To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10\^11 particle units (PU) to healthy adults. Secondary Objectives: * To evaluate the antibody response to Monovalent Chimpanzee Adenoviral Ve...
What is the current status of trial NCT04723602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-01-06. Estimated completion is 2021-12-14.
What interventions are being tested in trial NCT04723602?
The interventions under investigation include: cAd3-Marburg (BIOLOGICAL), cAd3-EBO-S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04723602?
This trial is sponsored by Albert B. Sabin Vaccine Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.